https://www.proqr.com/employee/meet-lorenza-rd-team-manager 2026-01-20T09:39:42+00:00 0.5 https://www.proqr.com/employee/meet-lemelinda-senior-researcher 2026-01-20T09:38:24+00:00 0.5 https://www.proqr.com/employee/meet-david-senior-scientist 2026-01-20T09:36:39+00:00 0.5 https://www.proqr.com/employee/meet-carles-researcher 2026-01-22T15:47:29+00:00 0.5 https://www.proqr.com/employee/meet-seda-senior-director-research-strategy-and-innovation 2026-03-03T16:34:06+00:00 0.5 https://www.proqr.com/events/2020-06-world-ophthalmology-congress-woc 2021-12-28T11:58:03+00:00 0.5 https://www.proqr.com/events/2020-07-asrs-annual-meeting-2020 2021-12-28T11:57:52+00:00 0.5 https://www.proqr.com/events/2020-10-euretina-annual-meeting-2020 2021-12-28T11:58:23+00:00 0.5 https://www.proqr.com/events/2020-10-american-academy-of-optometry-aaopt-annual-meeting-2020 2021-12-28T11:58:13+00:00 0.5 https://www.proqr.com/events/2020-11-american-academy-of-ophthalmology-aao-annual-meeting-2020 2021-12-28T11:55:33+00:00 0.5 https://www.proqr.com/events/2020-09-fall-eye-on-the-future-forum-eff-summit-2020 2021-12-28T11:59:33+00:00 0.5 https://www.proqr.com/events/2020-09-citis-15th-annual-biopharma-virtual-conference 2020-09-03T18:52:24+00:00 0.5 https://www.proqr.com/events/2020-09-hc-wainwright-22nd-annual-global-investment-conference 2020-09-03T18:52:48+00:00 0.5 https://www.proqr.com/events/2020-09-cantor-virtual-global-healthcare-conference 2020-09-03T18:53:15+00:00 0.5 https://www.proqr.com/events/2020-10-chardan-virtual-4th-annual-genetic-medicines-conference 2020-09-03T18:50:20+00:00 0.5 https://www.proqr.com/events/2020-07-expert-perspectives-series-lca10-and-sepofarsen 2021-12-28T11:56:29+00:00 0.5 https://www.proqr.com/events/2020-06-expert-perspectives-series-usher-syndrome-and-retinitis-pigmentosa 2021-12-28T11:57:38+00:00 0.5 https://www.proqr.com/events/2019-10-proqr-top-line-results-phase-12-trial-of-sepofarsen-in-lca10-patients 2021-12-28T11:57:09+00:00 0.5 https://www.proqr.com/events/2020-12-3rd-annual-evercore-isi-virtual-healthconx-conference 2020-11-13T16:57:25+00:00 0.5 https://www.proqr.com/events/2021-11-american-academy-of-ophthalmology-aao-annual-meeting-2021 2021-12-28T11:55:21+00:00 0.5 https://www.proqr.com/events/2021-09-euretina-annual-meeting-2021 2021-12-28T11:55:08+00:00 0.5 https://www.proqr.com/events/2021-05-the-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting-2021 2021-12-28T11:54:56+00:00 0.5 https://www.proqr.com/events/2021-01-hc-wainwright-virtual-bioconnect-2021-conference 2020-12-17T16:52:50+00:00 0.5 https://www.proqr.com/events/2021-02-rare-disease-day 2021-02-22T18:26:04+00:00 0.5 https://www.proqr.com/events/2021-02-evercore-isi-measuring-vision-webinar-part-1 2021-02-16T16:32:49+00:00 0.5 https://www.proqr.com/events/2021-02-evercore-isi-measuring-vision-webinar-part-2 2021-02-16T16:12:39+00:00 0.5 https://www.proqr.com/events/2021-02-expert-perspectives-series-disease-education-and-endpoints-in-usher-syndrome 2021-02-16T20:05:25+00:00 0.5 https://www.proqr.com/events/2021-04-american-association-for-pediatric-ophthalmology-aapos-virtual-meeting 2021-03-01T16:29:49+00:00 0.5 https://www.proqr.com/events/2021-03-hc-wainwright-global-life-sciences-conference 2021-03-02T19:20:46+00:00 0.5 https://www.proqr.com/events/2021-03-webcast-of-presentation-of-qr-421a-phase-12-stellar-trial-results 2021-03-24T12:07:49+00:00 0.5 https://www.proqr.com/events/2021-03-jmp-securities-grand-rounds-kol-call-prqr-phase-12-stellar-data-in-usher-syndrome 2021-03-25T14:58:10+00:00 0.5 https://www.proqr.com/events/2021-03-cantor-kol-call-to-review-phase-12-stellar-data-in-ushernsrp 2021-03-25T18:21:43+00:00 0.5 https://www.proqr.com/events/2021-04-eye-on-the-future-forum-spring-summit 2021-12-28T11:54:29+00:00 0.5 https://www.proqr.com/events/2021-04-kempen-life-sciences-conference 2021-04-22T18:18:06+00:00 0.5 https://www.proqr.com/events/2021-05-annual-general-meeting-virtual 2021-05-18T15:25:33+00:00 0.5 https://www.proqr.com/events/2021-06-jmp-securities-life-sciences-conference 2021-06-07T18:24:20+00:00 0.5 https://www.proqr.com/events/2021-08-hc-wainwright-ophthalmology-virtual-conference 2021-08-10T15:12:37+00:00 0.5 https://www.proqr.com/events/2021-09-citis-16th-annual-biopharma-virtual-conference 2021-08-31T19:07:21+00:00 0.5 https://www.proqr.com/events/2021-09-hc-wainwright-23rd-annual-global-investment-conference 2021-08-31T19:13:49+00:00 0.5 https://www.proqr.com/events/2021-09-cantor-global-healthcare-conference 2021-08-31T19:18:47+00:00 0.5 https://www.proqr.com/events/2021-10-chardan-5th-annual-genetic-medicines-conference 2021-09-01T19:25:21+00:00 0.5 https://www.proqr.com/events/2021-09-axiomer-investor-call 2021-12-28T11:53:41+00:00 0.5 https://www.proqr.com/events/2021-10-eff-fall-virtual-summit-2021-the-science-of-rna-therapies 2021-12-28T11:53:26+00:00 0.5 https://www.proqr.com/events/2021-11-stifel-2021-virtual-healthcare-conference 2021-11-03T20:46:23+00:00 0.5 https://www.proqr.com/events/2021-12-evercore-isi-4th-annual-healthconx-conference 2021-11-03T20:52:48+00:00 0.5 https://www.proqr.com/events/2021-11-proqr-analyst-event 2021-12-28T11:46:35+00:00 0.5 https://www.proqr.com/events/2022-02-svb-leerink-2022-global-healthcare-conference 2022-02-07T19:01:49+00:00 0.5 https://www.proqr.com/events/2022-02-conference-call-top-line-results-phase-23-illuminate-trial 2022-02-11T12:03:14+00:00 0.5 https://www.proqr.com/events/2022-05-arvo-annual-meeting 2022-03-08T13:41:25+00:00 0.5 https://www.proqr.com/events/2022-05-tides-usa 2022-03-08T13:47:09+00:00 0.5 https://www.proqr.com/events/2022-03-cantor-virtual-rare-orphan-disease-summit 2022-03-23T18:39:40+00:00 0.5 https://www.proqr.com/events/2022-04-conference-call-additional-sepofarsen-analyses-and-company-strategy-update 2022-04-13T12:07:13+00:00 0.5 https://www.proqr.com/events/2022-04-kempen-life-sciences-conference 2022-04-19T18:33:23+00:00 0.5 https://www.proqr.com/events/2022-04-retinal-cell-and-gene-therapy-innovation-summit 2022-04-26T20:10:03+00:00 0.5 https://www.proqr.com/events/2022-06-annual-general-meeting 2022-06-01T12:25:53+00:00 0.5 https://www.proqr.com/events/2022-06-life-sci-2nd-annual-genetic-medicines-symposium 2022-06-27T14:42:15+00:00 0.5 https://www.proqr.com/events/2022-08-investor-call 2022-08-11T11:00:47+00:00 0.5 https://www.proqr.com/events/2022-11-stifel-2022-healthcare-conference 2022-11-02T17:56:54+00:00 0.5 https://www.proqr.com/events/2022-11-tides-europe-oligonucleotide-and-peptide-therapeutics-conference 2022-11-08T15:21:38+00:00 0.5 https://www.proqr.com/events/2022-12-proqr-investoranalyst-webcast-lilly-partnership-expansion-and-axiomer-overview 2022-12-22T13:16:02+00:00 0.5 https://www.proqr.com/events/2023-03-proqr-therapeutics-virtual-rd-event-2023 2023-03-29T15:43:44+00:00 0.5 https://www.proqr.com/events/2023-03-oligonucleotide-and-precision-therapeutics-opt-congress 2023-03-08T12:17:12+00:00 0.5 https://www.proqr.com/events/2023-03-rna-leaders-europe-congress 2023-03-08T12:17:21+00:00 0.5 https://www.proqr.com/events/2023-03-rna-editing-gordon-research-conference-grc 2023-03-08T12:17:33+00:00 0.5 https://www.proqr.com/events/2023-04-van-lanschot-kempen-life-sciences-conference-amsterdam 2023-04-17T15:05:11+00:00 0.5 https://www.proqr.com/events/2023-05-stifel-2023-tailoring-genes-genetic-medicines-day 2023-04-17T15:25:27+00:00 0.5 https://www.proqr.com/events/2023-05-annual-general-meeting 2023-04-18T11:43:11+00:00 0.5 https://www.proqr.com/events/2023-05-oligonucleotide-and-peptide-therapeutics-conference-tides-usa 2023-05-09T12:01:03+00:00 0.5 https://www.proqr.com/events/2023-09-hc-wainwright-25th-annual-global-investment-conference 2023-09-06T15:15:46+00:00 0.5 https://www.proqr.com/events/2023-10-chardan-7th-annual-genetic-medicines-conference 2023-10-10T16:03:35+00:00 0.5 https://www.proqr.com/events/2024-04-van-lanschot-kempen-life-sciences-conference 2024-04-10T15:48:28+00:00 0.5 https://www.proqr.com/events/2024-05-american-society-of-gene-cell-therapy-asgct-annual-meeting 2024-05-09T15:21:22+00:00 0.5 https://www.proqr.com/events/2024-05-annual-general-meeting 2024-04-23T17:43:57+00:00 0.5 https://www.proqr.com/events/2024-05-asgct-investor-webcast 2024-05-15T17:59:03+00:00 0.5 https://www.proqr.com/events/2024-09-2024-cantor-global-healthcare-conference 2024-09-10T16:19:19+00:00 0.5 https://www.proqr.com/events/2024-12-analyst-and-investor-event 2024-12-11T16:36:44+00:00 0.5 https://www.proqr.com/events/2025-04-van-lanschot-kempen-life-sciences-conference 2025-03-31T12:32:53+00:00 0.5 https://www.proqr.com/events/2025-06-annual-general-meeting 2025-05-01T11:58:23+00:00 0.5 https://www.proqr.com/events/2025-05-citizens-life-sciences-conference 2025-05-02T00:01:01+00:00 0.5 https://www.proqr.com/events/2025-10-hc-wainwright-genetic-medicines-virtual-conference 2025-10-13T11:49:08+00:00 0.5 https://www.proqr.com/events/2025-10-hc-wainwright-liver-disease-virtual-conference 2025-10-13T11:51:26+00:00 0.5 https://www.proqr.com/events/2025-10-chardans-9th-annual-genetic-medicines-conference 2025-10-13T11:55:05+00:00 0.5 https://www.proqr.com/events/2025-11-virtual-investor-and-analyst-event-on-ax-0810 2025-11-03T17:16:29+00:00 0.5 https://www.proqr.com/events/2025-12-8th-annual-evercore-healthcare-conference 2025-12-01T01:33:33+00:00 0.5 https://www.proqr.com/events/2026-03-citizens-life-sciences-conference 2026-03-03T15:22:39+00:00 0.5 https://www.proqr.com/events/2026-04-virtual-investor-and-analyst-event 2026-03-25T15:44:35+00:00 0.5 https://www.proqr.com/events/2026-04-raymond-james-biotech-innovation-symposium 2026-04-02T19:45:14+00:00 0.5 https://www.proqr.com/events/2026-04-van-lanschot-kempen-life-sciences-conference 2026-04-02T19:47:16+00:00 0.5 https://www.proqr.com/node/230 2026-01-20T12:56:34+00:00 0.5 https://www.proqr.com/careers 2026-01-16T09:29:21+00:00 0.5 https://www.proqr.com/science 2026-01-26T15:27:03+00:00 0.5 https://www.proqr.com/investors-and-media 2026-02-18T10:25:59+00:00 0.5 https://www.proqr.com/careers/vacancies 2026-02-20T15:06:36+00:00 0.5 https://www.proqr.com/science/pipeline 2026-01-13T13:50:26+00:00 0.5 https://www.proqr.com/careers/recruitment-experience 2025-07-24T09:44:16+00:00 0.5 https://www.proqr.com/pipeline 2026-01-26T15:25:53+00:00 0.5 https://www.proqr.com/leadership 2025-11-12T13:46:23+00:00 0.5 https://www.proqr.com/disclaimer 2020-10-05T09:51:10+00:00 0.5 https://www.proqr.com/privacy 2023-07-06T10:47:49+00:00 0.5 https://www.proqr.com/investors-media/financials-and-filings 2026-03-16T09:25:40+00:00 0.5 https://www.proqr.com/investors-media/corporate-governance 2026-03-11T22:16:03+00:00 0.5 https://www.proqr.com/investors-media/analyst-coverage 2026-03-12T11:17:05+00:00 0.5 https://www.proqr.com/science/axiomer-technology-rna-base-editing 2026-02-18T12:47:22+00:00 0.5 https://www.proqr.com/presentations-publications 2026-02-26T13:49:43+00:00 0.5 https://www.proqr.com/contact 2025-03-03T14:49:30+00:00 0.5 https://www.proqr.com/press-releases/email-alerts 2023-07-28T10:42:51+00:00 0.5 https://www.proqr.com/about-proqr-therapeutics 2023-12-20T12:48:26+00:00 0.5 https://www.proqr.com/founding-story 2022-03-08T15:10:17+00:00 0.5 https://www.proqr.com/investors-media/stock-info 2022-12-15T10:56:41+00:00 0.5 https://www.proqr.com/science/RNA-therapy 2023-12-20T12:54:31+00:00 0.5 https://www.proqr.com/investors-media/financials-and-filings/shareholder-meetings-archive 2025-05-21T14:21:40+00:00 0.5 https://www.proqr.com/investors-media/proqr-corporate-presentation 2025-03-18T14:52:19+00:00 0.5 https://www.proqr.com/partnerships 2024-12-11T13:14:53+00:00 0.5 https://www.proqr.com/privacy-statement-job-applicants 2022-11-25T10:48:21+00:00 0.5 https://www.proqr.com/science/axiomer-technology/axiomer-technology-explained 2024-08-20T13:59:56+00:00 0.5 https://www.proqr.com/careers/vacancies/jobs/open-application 2025-06-26T11:35:58+00:00 0.5 https://www.proqr.com/developing-potentially-life-changing-medicines-for-patients-with-high-unmet-medical-need 2026-01-08T16:46:47+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-positive-findings-from-an-interim-analysis-in-the-phase-12-trial-of 2020-03-31T10:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-findings-from-phase-12-interim-analysis-of-qr-421a-for-usher-syndrome 2021-12-28T10:48:22+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-fourth-quarter-and-full-year-2019-results-and-provides-business 2020-02-26T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-cowen-and-company-40th-annual-health-care-conference 2020-02-24T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-therapeutics-teams-up-with-the-foundation-fighting-blindness-and-blueprint-genetics-to-support-the-my-retina-trackerr-program-for-people-living-with-inherited-retinal-diseases 2020-08-05T08:43:17+00:00 0.5 https://www.proqr.com/press-releases/proqr-receives-rare-pediatric-disease-designation-from-fda-for-qr-421a 2021-12-28T10:49:09+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-first-patient-dosed-in-phase-12-aurora-trial-of-qr-1123-for 2019-12-11T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-receives-orphan-drug-designation-from-fda-for-qr-1123-for-autosomal-dominant 2019-11-21T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-upcoming-scientific-conferences 2019-11-18T12:23:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-upcoming-investor-conferences 2019-11-13T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-recent-progress-and-financial-results-for-the-third-quarter-of-2019 2020-04-10T12:25:17+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-closing-of-underwritten-public-offering-of-ordinary-shares-with-full 2019-10-18T12:20:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-prices-50-million-underwritten-public-offering-of-ordinary-shares 2019-10-16T03:17:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-receives-rare-pediatric-disease-designation-from-fda-for-sepofarsen-for-the 2019-10-15T20:08:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-annonce-des-premiers-resultats-positifs-pour-lessai-de-phase-12-du-sepofarsen 2019-10-11T10:03:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-positive-top-line-results-from-the-phase-12-study-of-sepofarsen-in-lca10-patients 2021-12-28T10:43:31+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-top-line-results-from-the-phase-12-study-of-sepofarsen-in-lca10 2019-10-07T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-two-investor-conferences-in-october 2019-09-30T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-first-quarter-2020-operating-and-financial-results 2020-05-07T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-annual-meeting-of-shareholders-2020 2021-04-20T08:25:24+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-virtual-presentation-of-phase-12-sepofarsen-data-through-the-association-for-research-in-vision-and-ophthalmology-arvo 2021-12-28T10:47:40+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-expert-perspectives-conference-call-series 2020-06-12T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-receives-fast-track-designation-from-fda-for-qr-1123-for-autosomal-dominant 2019-09-09T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-1123-in-patients-with 2019-08-12T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-financial-results-for-the-second-quarter-of-2019 2019-08-07T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/lagence-europeenne-des-medicaments-accorde-lacces-prime-au-sepofarsen-de-proqr-pour 2019-07-29T16:37:00+00:00 0.5 https://www.proqr.com/press-releases/european-medicines-agency-grants-prime-access-to-proqrs-sepofarsen-for-lebers 2019-07-29T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-presentation-on-qr-421a-program-in-ophthalmology-at-usher-syndrome 2019-07-02T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-the-jmp-securities-life-sciences-conference 2019-06-03T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-the-rbc-capital-markets-healthcare-conference 2019-05-15T10:59:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-financial-results-for-the-first-quarter-of-2019 2019-05-08T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-three-scientific-conferences-in-april 2019-04-22T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-nominates-bart-filius-coo-and-cfo-at-galapagos-and-theresa-heggie-head-of 2019-04-18T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-annual-meeting-of-shareholders-0 2019-04-18T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-doses-first-patient-in-phase-23-illuminate-trial-of-sepofarsen-for-lca10 2019-04-15T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-the-hc-wainwright-global-life-sciences-conference 2019-04-01T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-spins-out-all-dystrophic-epidermolysis-bullosa-activities-into-newly-formed 2019-03-26T20:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-traite-le-premier-patient-dans-lessai-stellar-de-phase-12-du-qr-421a-pour-le 2019-03-11T16:45:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-doses-first-patient-in-phase-12-stellar-trial-of-qr-421a-for-usher-syndrome 2019-03-14T14:02:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-cowen-health-care-conference 2019-03-05T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-reports-fourth-quarter-and-full-year-2018-operating-and-financial-results 2019-02-27T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-proqr-vision-2023-strategy-at-its-annual-rd-day 2019-01-29T13:31:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-reaches-agreement-with-the-fda-on-design-of-phase-23-pivotal-trial-for 2019-01-07T12:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-host-rd-day-in-new-york-on-january-29 2019-01-03T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-receives-fast-track-designation-from-fda-for-qr-421a-for-usher-syndrome-type-2 2019-01-02T12:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-therapeutics-added-to-nasdaq-biotechnology-index 2018-12-24T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-annonce-la-publication-dans-nature-medicine-des-donnees-du-qr-110-pour 2018-12-18T15:27:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-publication-in-nature-medicine-of-qr-110-data-for-lebers-congenital 2018-12-17T16:52:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-strategic-changes-to-the-management-team-and-key-new-hires 2018-12-13T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-receives-eu-47-million-in-innovation-credit-from-dutch-government-for-qr-110 2018-12-10T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-421a-in-usher 2018-12-04T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-the-evercore-isi-healthconx-conference 2018-11-20T12:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-financial-results-for-the-third-quarter-of-2018 2018-11-07T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-presentations-at-the-european-oligonucleotide-and-peptide 2018-10-31T11:02:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-lizenziert-weltweite-rechte-fur-arzneimittelkandidaten-fur-die-augenheilkunde 2018-10-30T22:15:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-in-licenses-worldwide-rights-to-ophthalmology-drug-candidate-from-ionis 2018-10-29T11:33:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-the-chardan-genetic-medicines-conference 2018-10-02T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-presentations-at-the-ots-annual-meeting 2018-09-24T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-closing-of-underwritten-public-offering-of-ordinary-shares-with-0 2018-09-11T20:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-prices-906-million-underwritten-public-offering-of-ordinary-shares 2018-09-07T08:20:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-proposed-underwritten-public-offering-of-ordinary-shares-2018 2021-03-30T21:51:10+00:00 0.5 https://www.proqr.com/press-releases/proqr-annonce-des-resultats-intermediaires-positifs-pour-un-essai-clinique-de-phase 2018-09-05T09:46:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-positive-interim-results-from-phase-12-clinical-trial-of-qr-110-in-lca10-patients-and-plans-to-start-a-phase-23-pivotal-trial 2021-12-28T10:39:24+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-interim-phase-12-results-for-qr-110-in-lebers-congenital-amaurosis 2018-08-15T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-financial-results-for-the-second-quarter-of-2018 2018-08-08T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-publication-on-qr-110-for-lebers-congenital-amaurosis-10-in-the 2018-08-01T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-presentations-on-programs-in-ophthalmology-at-conferences-in-july 2018-07-12T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-initiates-phase-12-clinical-trial-of-qr-313-for-dystrophic-epidermolysis 2018-06-28T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-the-jmp-life-sciences-conference 2018-06-14T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-receives-up-to-5-million-in-partnership-with-eb-research-partnership-and-eb 2018-06-12T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-presentations-at-ecfs-on-eluforsen-for-f508del-cystic-fibrosis-and 2018-06-04T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-appoints-yi-tao-yu-phd-to-its-scientific-advisory-board 2018-05-23T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-results-for-the-first-quarter-of-2018 2018-05-09T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-conference-presentations-for-axiomerr-rna-editing-technology-and-qr 2018-04-30T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-provides-enrollment-update-on-qr-110-clinical-trial-and-highlights 2018-04-23T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-annual-meeting-of-shareholders-1 2018-04-11T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-appoints-adar-expert-dr-peter-a-beal-to-scientific-advisory-board-to-focus-on 2018-04-10T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-two-upcoming-conferences 2018-04-03T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-upcoming-investor-conference 2018-03-05T12:02:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-results-for-the-fourth-quarter-and-full-year-2017-and-provides 2018-02-28T12:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-supports-rare-disease-day-2018-and-honors-henri-a-termeer 2018-02-27T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/foundation-fighting-blindness-will-provide-up-to-75-million-in-funding-to-develop 2018-02-12T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-upcoming-scientific-meeting-and-investor-conference 2018-02-06T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-and-galapagos-announce-research-collaboration-on-fibrosis-targets-using-proqrs 2018-01-08T12:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-extraordinary-general-meeting-of-shareholders 2017-12-27T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-receives-orphan-drug-designation-from-ema-for-drug-candidate-qr-313-for 2017-11-29T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-the-annual-piper-jaffray-healthcare-conference 2017-11-21T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-results-for-the-third-quarter-of-2017 2017-11-20T12:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-prices-approximately-20-million-underwritten-public-offering-and-concurrent 2017-11-14T12:44:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-proposed-public-offering-of-ordinary-shares-2017 2021-03-30T21:55:38+00:00 0.5 https://www.proqr.com/press-releases/proqr-doses-first-lca-10-patient-in-clinical-trial-of-qr-110-proqrs-lead-program-for 2017-11-13T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-appoints-thaddeus-dryja-md-to-scientific-advisory-board 2017-11-09T12:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-eurotides-conference 2017-10-31T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-management-change-and-key-promotions 2017-10-26T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-presentations-and-investor-analyst-event-at-the-north-american 2017-10-24T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-the-chardan-inaugural-gene-therapy-conference 2017-10-06T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-positive-top-line-results-from-a-phase-1b-study-of-qr-010-in 2017-09-25T20:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-presents-in-vivo-proof-of-concept-data-for-the-axiomerr-rna-editing-platform 2017-09-21T11:05:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-two-investor-conferences-in-september 2017-09-21T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-receives-orphan-drug-designation-from-fda-for-drug-candidate-qr-313-for 2017-09-19T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-spins-out-amylon-therapeutics-as-a-privately-held-company-focused-on-central 2017-09-12T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqrs-drug-candidate-qrx-421-for-usher-syndrome-receives-orphan-drug-designation 2017-09-05T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-completes-dosing-of-cystic-fibrosis-patients-in-qr-010-phase-1b-trial 2017-08-29T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-strengthens-its-scientific-advisory-board-with-the-appointment-of-dr-phil 2017-08-28T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-results-for-the-second-quarter-of-2017 2017-08-16T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqrs-drug-candidate-qrx-411-for-usher-syndrome-receives-orphan-drug-designation 2017-07-05T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-rd-day-highlights-progress-on-pipeline-and-introduces-axiomerr-a-novel 2017-06-15T11:04:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-participate-in-a-cystic-fibrosis-panel-discussion-during-the-jmp-securities 2017-06-13T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-qr-010-data-at-the-european-cystic-fibrosis-society-conference-and 2017-06-08T13:03:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-receives-fast-track-designation-from-the-fda-for-qr-110-for-lebers-congenital-amaurosis-type-10 2021-12-28T10:32:01+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-results-for-the-first-quarter-of-2017 2017-05-17T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-remembers-co-founder-henri-termeer-after-his-unexpected-passing 2017-05-15T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-rd-day-in-new-york-on-june-15 2017-05-09T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-its-ophthalmology-pipeline-at-arvo-highlighting-programs-in-lebers 2017-05-01T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-clearance-of-ind-application-to-start-clinical-trial-for-qr-110-in 2017-04-27T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-the-deutsche-bank-health-care-conference 2017-04-20T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-annual-meeting-of-shareholders-2 2017-04-10T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-the-grant-of-two-key-patents-protecting-qr-010-for-cystic-fibrosis 2017-04-03T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-appoints-david-m-rodman-md-as-chief-development-strategy-officer 2017-03-27T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-two-upcoming-investor-conferences-in-march 2017-03-01T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-results-for-the-fourth-quarter-and-full-year-2016-and-provides-a 2017-02-28T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/on-a-shared-quest-to-find-treatments-for-rare-diseases-proqr-supports-rare-disease 2017-02-27T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-the-leerink-partners-global-healthcare-conference 2017-02-07T12:02:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-results-for-the-third-quarter-of-2016 2016-11-14T12:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-that-qr-010-meets-the-primary-endpoint-in-a-proof-of-concept-study 2016-10-27T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-clinical-data-presentations-and-investor-analyst-event-at-nacfc 2016-09-27T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-scientific-and-investor-conferences-in-september 2016-09-06T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-results-for-the-second-quarter-of-2016 2016-08-17T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-receives-fast-track-designation-from-fda-for-qr-010-for-cystic-fibrosis 2016-07-19T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-release-topline-data-from-proof-of-concept-study-of-qr-010-in-cystic 2016-06-21T13:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqrs-drug-candidate-qr-110-for-lebers-congenital-amaurosis-type-10-receives-ema 2016-06-01T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-presentations-at-the-european-cf-conference-and-the-jmp-life-science 2016-06-01T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-results-for-the-first-quarter-of-2016 2016-05-18T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-an-investor-and-analyst-event-and-pre-clinical-data-presentations 2016-04-25T20:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-annual-meeting-of-shareholders-3 2016-04-07T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-highlight-a-growing-pipeline-during-a-research-development-day-and-present 2016-03-01T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-results-for-the-fourth-quarter-and-full-year-2015 2016-02-17T12:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-the-leerink-partners-global-healthcare-conference-0 2016-02-03T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-rd-day-and-provides-update-on-innovation-portfolio 2015-11-30T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-results-for-the-third-quarter-of-2015-and-provides-update-on 2015-11-23T11:30:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-an-investor-and-analyst-event-and-pre-clinical-data-presentations-0 2015-10-01T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-the-leerink-partners-4th-annual-rare-disease-roundtable 2015-09-23T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-a-proof-of-concept-nasal-potential-difference-study-of-qr-010-is 2015-09-14T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-results-for-the-second-quarter-of-2015 2015-08-19T11:59:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-enrollment-has-started-in-global-phase-1b-study-of-qr-010-in-cystic 2015-06-26T11:54:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-the-jmp-securities-life-science-conference 2015-06-16T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-therapeutics-announces-results-for-the-first-quarter-of-2015 2015-05-21T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-therapeutics-announces-annual-shareholder-meeting 2015-04-29T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-two-upcoming-investor-conferences-in-may 2015-04-29T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-therapeutics-announces-results-for-the-fourth-quarter-and-full-year-2014 2015-02-26T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-the-2015-leerink-global-healthcare-conference 2015-02-04T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-therapeutics-announces-results-for-the-third-quarter-of-2014 2014-11-24T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares 2021-12-28T10:20:01+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-pricing-of-initial-public-offering 2021-12-28T10:18:51+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-expert-perspectives-call-on-lca10-and-sepofarsen 2021-12-28T10:47:25+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-30-million-strategic-convertible-debt-financing-agreement-with 2020-07-14T20:30:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-strengthens-scientific-advisory-board-with-leaders-in-inherited-retinal-disease-and-rna-therapy 2020-08-05T08:44:03+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-second-quarter-2020-operating-and-financial-results 2020-08-30T08:50:24+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-participate-in-upcoming-investor-conferences 2020-09-04T13:24:36+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-virtual-presentations-at-scientific-conferences 2020-09-24T20:10:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-appoints-naveed-shams-md-phd-as-chief-scientific-officer 2020-10-05T11:09:52+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-virtual-presentations-at-american-academy-of-ophthalmology-aao 2021-12-28T10:46:47+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-third-quarter-2020-operating-and-financial-results 2021-02-25T23:15:10+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-3rd-annual-evercore-isi-virtual-healthconx-conference 2020-11-18T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-webcast-of-presentation-at-upcoming-hc-wainwright-bioconnect-conference 2020-12-18T12:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-completes-enrollment-of-its-pivotal-trial-of-sepofarsen-for-the-treatment-of-lca10 2022-01-24T13:08:14+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-expert-perspectives-call-on-disease-education-and-endpoints-in-usher-syndrome 2022-01-24T13:07:28+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-fourth-quarter-and-full-year-2020-operating-and-financial-results 2021-02-25T23:14:55+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-webcast-of-presentation-at-upcoming-hc-wainwright-global-life-sciences-conference 2021-03-02T21:30:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-results-from-phase-12-trial-of-qr-421a-for-usher-syndrome 2021-03-17T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-positive-results-from-clinical-trial-of-qr-421a-in-usher-syndrome-and-plans-to-start-pivotal-trials 2022-01-24T13:06:41+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-proposed-underwritten-public-offering-of-ordinary-shares-1 2021-03-30T20:06:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-proposed-underwritten-public-offering-of-ordinary-shares-2019 2021-03-30T21:45:11+00:00 0.5 https://www.proqr.com/press-releases/proqr-prices-90-million-underwritten-public-offering-of-ordinary-shares 2021-03-31T02:25:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-virtual-presentation-at-american-association-for-pediatric-ophthalmology-and-strabismus-aapos-2021 2022-01-24T13:06:15+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-closing-of-underwritten-public-offering-of-ordinary-shares-with-full-exercise-of-underwriters-option-to-purchase-additional-shares 2021-04-05T20:15:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-publication-in-nature-medicine-for-sepofarsen-in-leber-congenital-amaurosis-10 2022-01-24T13:05:47+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-annual-meeting-of-shareholders 2021-04-20T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-participation-in-upcoming-kempen-life-sciences-conference 2021-04-22T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-virtual-presentation-of-phase-12-sepofarsen-extension-trial-data-at-the-association-for-research-in-vision-and-ophthalmology-arvo-2021 2022-01-24T13:05:15+00:00 0.5 https://www.proqr.com/press-releases/proqr-therapeutics-and-yarrow-biotechnology-an-rtw-investments-lp-incubated-company-announce-exclusive-worldwide-license-and-discovery-collaboration-for-undisclosed-target 2022-01-24T13:04:48+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-first-quarter-2021-operating-and-financial-results 2023-08-21T11:44:39+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-upcoming-jmp-securities-life-sciences-conference 2021-06-10T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-second-quarter-2021-operating-and-financial-results 2023-08-21T11:45:36+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-webcast-of-presentation-at-upcoming-hc-wainwright-ophthalmology-virtual-conference 2021-08-13T08:28:21+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-upcoming-investor-conferences 2021-09-03T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-virtual-presentation-at-euretina-2021 2022-01-24T13:02:34+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-axiomerr-rna-editing-licensing-and-research-collaboration-with-lilly 2022-01-24T13:02:04+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-conference-call-to-discuss-the-axiomerr-rna-editing-platform 2021-09-08T20:15:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-appoints-theresa-heggie-as-chief-commercial-officer 2022-01-24T13:01:40+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-third-quarter-2021-operating-and-financial-results 2023-08-21T11:45:14+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-upcoming-investor-conferences-in-november-and-december 2021-11-08T21:30:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-webcast-virtual-analyst-event-on-november-18 2021-11-11T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-highlights-from-analyst-event 2022-01-24T13:00:19+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-first-patients-dosed-in-phase-23-pivotal-trials-of-qr-421a-for-ush2a-mediated-retinitis-pigmentosa 2022-01-24T13:06:57+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-amendment-to-convertible-debt-financing-agreement-with-pontifax-ventures-and-kreos-capital 2021-12-30T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-last-patient-has-completed-12-month-visit-in-phase-23-illuminate-trial-of-sepofarsen 2022-01-04T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-upcoming-svb-leerink-conference 2022-02-07T21:30:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-top-line-results-from-phase-23-illuminate-trial-of-sepofarsen-in-cep290-mediated-lca10 2022-02-11T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-fourth-quarter-and-full-year-2021-operating-and-financial-results 2023-08-21T11:46:02+00:00 0.5 https://www.proqr.com/press-releases/proqr-appoints-john-maraganore-phd-as-strategic-advisor-to-the-supervisory-board 2022-03-07T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-participate-in-the-cantor-virtual-rare-orphan-disease-summit 2022-03-23T20:30:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-axiomer-rna-editing-platform-technology-at-rna-editing-summit 2022-04-04T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-additional-sepofarsen-illuminate-trial-analyses-and-provides-update-on-company-strategy 2022-04-13T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-participate-in-the-kempen-life-sciences-conference 2022-04-19T20:30:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-the-retinal-cell-and-gene-therapy-innovation-summit-and-the-association-for-research-in-vision-and-ophthalmology-arvo-2022 2022-04-26T20:10:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-first-quarter-2022-operating-and-financial-results 2023-08-21T11:41:15+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-its-axiomerr-rna-editing-technology-at-the-oligonucleotide-and-peptide-therapeutics-conference-tides-usa-2022 2022-05-09T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-annual-general-meeting-of-shareholders-and-provides-leadership-updates 2022-06-01T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-participate-in-the-lifesci-2nd-annual-genetic-medicines-symposium 2022-06-28T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-second-quarter-2022-operating-and-financial-results 2023-08-21T11:40:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-focus-exclusively-on-axiomer-rna-editing-technology-and-partner-ophthalmology-programs 2023-08-21T11:06:39+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-webcast-of-presentation-at-the-upcoming-stifel-2022-healthcare-conference 2022-11-03T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-third-quarter-2022-operating-and-financial-results 2023-08-21T11:36:43+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-its-axiomerr-rna-editing-technology-at-the-oligonucleotide-and-peptide-therapeutics-conference-tides-europe-2022 2022-11-21T12:57:04+00:00 0.5 https://www.proqr.com/press-releases/lilly-and-proqr-to-expand-rna-editing-collaboration 2022-12-22T11:21:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-conference-call-to-discuss-axiomerr-rna-editing-platform 2022-12-22T11:20:04+00:00 0.5 https://www.proqr.com/press-releases/proqr-therapeutics-to-host-virtual-rd-event-on-march-29-2023 2023-03-01T07:29:48+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-at-upcoming-scientific-and-industry-conferences 2023-03-07T15:56:40+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-successful-defense-of-a-key-axiomerr-patent-protecting-adar-mediated-rna-editing 2023-03-14T15:55:08+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-initial-pipeline-targets-and-highlights-axiomerr-rna-editing-platform-technology-at-rd-event 2023-03-30T09:46:06+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-annual-meeting-of-shareholders-to-be-held-may-17-2023 2023-04-18T13:24:20+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-upcoming-investor-conferences-in-april-and-may 2023-04-20T12:12:34+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-its-axiomerr-rna-editing-technology-at-tides-usa-2023 2023-05-09T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-first-quarter-2023-operating-and-financial-results 2023-08-21T11:42:22+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-present-data-on-its-axiomerr-rna-editing-technology-at-rna-editing-summit 2023-07-06T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-therapeutics-and-laboratoires-thea-announce-agreement-for-thea-to-acquire-proqrs-sepofarsen-and-ultevursen-ophthalmic-assets 2023-08-21T10:54:06+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-second-quarter-2023-operating-and-financial-results 2023-08-03T14:23:59+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-webcast-of-presentation-at-the-upcoming-hc-wainwright-25th-annual-global-investment-conference 2023-09-07T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-therapeutics-provides-update-on-ophthalmic-assets 2023-09-27T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-participation-in-the-chardan-7th-annual-genetic-medicines-conference 2023-09-28T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-strengthens-leading-intellectual-property-estate-for-adar-mediated-rna-editing 2023-11-06T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-third-quarter-2023-operating-and-financial-results 2023-11-07T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-therapeutics-announces-transaction-completed-for-thea-to-acquire-sepofarsen-and-ultevursen-ophthalmic-assets 2023-12-08T12:30:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-and-rett-syndrome-research-trust-join-forces-with-axiomertm-rna-editing-collaboration 2024-01-05T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-highlights-new-platform-data-from-presentation-on-axiomertm-rna-editing-technology-at-deaminet-2024 2024-01-19T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-japanese-axiomertm-patent-upheld-following-opposition-against-its-leading-ip-estate-for-adar-mediated-rna-editing 2024-02-15T12:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-year-end-2023-operating-and-financial-results 2024-03-13T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-achieves-successful-defense-of-new-challenge-to-its-axiomertm-ip-portfolio 2024-04-19T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-highlights-upcoming-presentations-on-axiomertm-rna-editing-at-asgct-27th-annual-meeting 2024-04-22T20:31:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-nominates-martin-maier-phd-to-board-and-announces-annual-meeting-of-shareholders-to-be-held-may-22-2024 2024-04-23T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-preclinical-proof-of-concept-data-for-ax-0810-axiomertm-rna-editing-program-targeting-ntcp-for-cholestatic-diseases 2024-05-08T12:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-first-quarter-2024-operating-and-financial-results 2024-05-09T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-presentation-on-its-axiomertm-rna-editing-technology-at-rna-editing-summit 2024-06-18T12:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-second-quarter-2024-operating-and-financial-results 2024-08-08T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-webcast-presentation-at-the-2024-cantor-global-healthcare-conference 2024-09-10T20:30:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society 2024-10-07T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-proposed-underwritten-public-offering-of-ordinary-shares 2024-10-22T20:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-prices-75-million-underwritten-public-offering-and-concurrent-private-placement 2024-10-23T02:15:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-closing-of-underwritten-public-offering-and-concurrent-private-placement 2024-10-25T20:45:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-third-quarter-2024-operating-and-financial-results 2024-11-07T12:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-therapeutics-to-host-virtual-analyst-and-investor-event-on-december-11-2024 2024-12-05T13:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-appoints-peter-a-beal-phd-as-chief-adar-scientist 2024-12-10T13:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-therapeutics-announces-81-million-in-new-funding-from-rett-syndrome-research-trust-to-expand-rna-editing-collaboration 2024-12-11T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-year-end-2024-operating-and-financial-results 2025-03-13T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-strengthens-leadership-with-appointments-of-cfo-and-cmo-to-support-next-phase-of-growth 2025-04-14T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-annual-general-meeting-of-shareholders-to-be-held-june-3-2025 2025-05-01T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-webcast-of-presentation-at-the-2025-citizens-life-sciences-conference 2025-05-02T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-first-quarter-2025-operating-and-financial-results 2025-05-08T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-upcoming-scientific-presentations-at-asgct-and-tides-conferences 2025-05-12T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-cta-submission-for-phase-1-study-of-ax-0810-targeting-ntcp 2025-06-26T20:30:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-upcoming-presentation-at-rna-editing-summit 2025-07-28T12:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-second-quarter-2025-operating-and-financial-results 2025-08-07T11:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-participate-in-upcoming-investor-conferences-in-october-2025 2025-10-13T12:30:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-receives-cta-authorization-for-ax-0810-and-announces-virtual-investor-and-analyst-event-on-november-3-2025 2025-10-20T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-third-quarter-2025-operating-and-financial-results 2025-11-06T12:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-participate-in-8th-annual-evercore-healthcare-conference 2025-12-01T13:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-encouraging-ax-0810-phase-1-safety-and-pk-data-development-candidate-selections-and-2026-outlook 2026-01-08T13:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-planned-changes-to-board-composition 2026-02-09T13:01:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-webcast-of-presentation-at-the-2026-citizens-life-sciences-conference 2026-03-03T21:30:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-announces-year-end-2025-operating-and-financial-results 2026-03-12T11:00:00+00:00 0.5 https://www.proqr.com/press-releases/proqr-to-host-virtual-investor-and-analyst-event-highlighting-pipeline-on-april-8-2026 2026-03-25T12:01:00+00:00 0.5 https://www.proqr.com/publications/full-field-stimulus-testing-fst-to-assess-sepofarsen-patient-response-in-leber-congenital-amaurosis-type-10 2023-08-08T15:13:44+00:00 0.5 https://www.proqr.com/publications/results-of-a-phase-1b2-trial-of-intravitreal-ivt-sepofarsen-qr-110-antisense-oligonucleotide-in-leber-congenital-amaurosis-10-lca10-due-to-pcys998x-mutation-in-the-cep290-gene 2023-08-08T15:15:06+00:00 0.5 https://www.proqr.com/publications/results-of-a-phase-1b2-trial-of-intravitreal-ivt-sepofarsen-qr-110-antisense-oligonucleotide-in-leber-congenital-amaurosis-10-lca10-due-to-pcys998x-mutation-in-the-cep290-gene-0 2021-12-28T10:59:20+00:00 0.5 https://www.proqr.com/publications/arvo-2021-russell-sr-et-al-safety-and-efficacy-of-sepofarsen-in-the-second-treated-eye-in-a-ph1b2-extension-trial-in-leber-congenital-amaurosis-type-10-lca10 2021-12-28T10:58:44+00:00 0.5 https://www.proqr.com/publications/axiomer/development-of-rna-base-editing-technologies-for-precision-medicines 2023-03-16T11:31:13+00:00 0.5 https://www.proqr.com/publications/axiomer/rational-design-of-rna-editing-guide-strands-cytidine-analogs-at-the-orphan-position 2023-03-16T11:31:40+00:00 0.5 https://www.proqr.com/publications/axiomer/structure-based-computational-approach-for-optimizing-oligonucleotides-for-a-to-i-editing 2023-03-16T11:32:03+00:00 0.5 https://www.proqr.com/publications/axiomer/progress-on-development-of-rna-base-editing-technologies-for-precision-medicines 2023-03-16T11:41:18+00:00 0.5 https://www.proqr.com/publications/axiomer/therapeutic-oligonucleotides-for-directing-site-specific-a-to-i-editing-by-endogenous-adar-enzymes 2023-03-16T11:32:25+00:00 0.5 https://www.proqr.com/publications/axiomer/therapeutic-potential-of-an-rna-editing-platform-using-editing-oligonucleotides-eons 2023-03-23T09:55:32+00:00 0.5 https://www.proqr.com/publications/axiomer/unlocking-the-potential-of-innovative-editing-oligonucleotides-to-address-liver-originated-disorders 2023-03-23T19:01:02+00:00 0.5 https://www.proqr.com/publications/analyst-investor-axiomer-technology-rd-event 2023-12-12T09:48:11+00:00 0.5 https://www.proqr.com/publications/unlocking-the-potential-of-innovative-editing-oligonucleotides-eons-to-address-liver-originated-disorders 2023-05-12T10:55:09+00:00 0.5 https://www.proqr.com/publications/exploring-the-potential-of-new-rna-editing-technologies-leveraging-adar-endogenous-machinery 2023-06-02T09:33:14+00:00 0.5 https://www.proqr.com/publications/harnessing-chemical-modifications-to-improve-adar-potency-and-unlock-axiomer-broad-applicability-0 2024-01-19T09:56:15+00:00 0.5 https://www.proqr.com/publications/axiomertm-an-rna-editing-technology-building-confidence-towards-clinical-development-deaminet-2024 2024-01-19T12:02:35+00:00 0.5 https://www.proqr.com/publications/annual-report-2025 2026-03-16T09:24:49+00:00 0.5 https://www.proqr.com/community-stories-and-news/top-notch-science-that-leads-to-a-treatment 2023-08-01T11:08:28+00:00 0.5 https://www.proqr.com/community-stories-and-news/a-new-way-of-designing-medicines 2022-09-26T15:48:44+00:00 0.5 https://www.proqr.com/community-stories-and-news/still-going-strong-one-challenge-after-another 2022-09-26T15:46:35+00:00 0.5 https://www.proqr.com/community-stories-and-news/always-excited-about-rna-therapies 2023-09-28T07:34:31+00:00 0.5 https://www.proqr.com/community-stories-and-news/rare-disease-day-2021 2022-09-26T15:54:18+00:00 0.5 https://www.proqr.com/community-stories-and-news/phase-23-illuminate-trial-results-of-sepofarsen-in-cep290-mediated-lca10 2023-08-01T11:07:02+00:00 0.5 https://www.proqr.com/community-stories-and-news/rare-disease-day-2022 2022-09-26T15:53:59+00:00 0.5 https://www.proqr.com/community-stories-and-news/proqr-update-and-additional-sepofarsen-illuminate-trial-analyses 2026-01-14T16:24:44+00:00 0.5 https://www.proqr.com/community-stories-and-news/building-an-inclusive-proqr 2026-02-20T10:15:05+00:00 0.5 https://www.proqr.com/community-stories-and-news/proqr-update-august-2022 2026-01-14T16:35:08+00:00 0.5 https://www.proqr.com/community-stories-and-news/proqr-at-tides-to-highlight-our-axiomer-technology 2026-02-20T09:34:54+00:00 0.5 https://www.proqr.com/community-stories-and-news/catching-up-with-returning-proqrian-rene-beukema 2026-02-20T09:33:55+00:00 0.5 https://www.proqr.com/community-stories-and-news/today-marks-an-expansion-of-the-proqr-and-lilly-partnership 2026-02-20T09:38:01+00:00 0.5 https://www.proqr.com/community-stories-and-news/exploring-why-companies-partner-their-technology 2026-02-20T09:36:07+00:00 0.5 https://www.proqr.com/community-stories-and-news/proqr-welcomes-a-new-generation-of-scientists 2024-02-21T14:04:32+00:00 0.5 https://www.proqr.com/community-stories-and-news/embracing-diversity-why-it-matters 2024-05-27T13:51:56+00:00 0.5 https://www.proqr.com/community-stories-and-news/proqr-driving-an-inclusive-culture-celebrating-pride-month 2026-01-14T16:15:58+00:00 0.5 https://www.proqr.com/community-stories-and-news/proqr-recognised-as-a-great-place-to-work 2025-04-24T09:24:06+00:00 0.5 https://www.proqr.com/careers/vacancies/jobs/6887556-principal-scientist-liver 2025-12-05T11:31:01+00:00 0.5 https://www.proqr.com/careers/vacancies/jobs/6928634-medical-director-cns 2025-12-15T11:19:01+00:00 0.5 https://www.proqr.com/careers/vacancies/jobs/7455374-senior-director-clinical-operations 2026-03-24T16:01:01+00:00 0.5